KBY Biotech Indexv0.0.34
Search
← Pipeline|SDG-1247

SDG-1247

Phase 1
By Schrodinger
Source: Trial-derived·Trials: 1
Modality
mAb
MOA
RAS(ON)i
Target
CD19
Pathway
Incretin
BCCProstate Ca
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Feb 2028
Phase 1Current
NCT06945438
1,646 pts·Prostate Ca
2018-07→2028-02·Terminated
1,646 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-121.9y awayInterim· Prostate Ca
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Termina…
Catalysts
Interim
2028-02-12 · 1.9y away
Prostate Ca
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06945438Phase 1Prostate CaTerminated1646NT-proBNP
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-8662PfizerNDA/BLACD19GLP-1ag
NVS-6974NovartisPreclinicalCD19HPK1i
VoxarasimodMerck & CoPhase 1/2CD19AuroraAi
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
TirarelsinTG TherapeuticsNDA/BLACD19IL-17i